A Study of MDV3100 to Evaluate Safety, Tolerability, Pharmacokinetics and Efficacy of in Prostate Cancer Patients
Status:
Completed
Trial end date:
2014-07-02
Target enrollment:
Participant gender:
Summary
This study is to evaluate safety, tolerability pharmacokinetics and efficacy of MDV3100 after
oral administration to patients with castration-resistant prostate cancer.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Astellas Pharma Inc
Collaborator:
Medivation LLC, a wholly owned subsidiary of Pfizer Inc.